B of A Securities Initiates Coverage On Apnimed with Buy Rating, Announces Price Target of $41

Benzinga Newsdesk www.benzinga.com Neutral 66.9%

Neg 0% Neu 66.9% Pos 0%

B of A Securities analyst Jason Gerberry initiates coverage on Apnimed (NASDAQ:APMD) with a Buy rating and announces Price Target of $41.